Article
TTT trial to test potential treatment for wet AMD
Mountain View, CA-IRIDEX Corp. has completed enrollment in a clinical trial for its TTT4CNV, to determine whether trans-pupillary thermotherapy (TTT) laser treatment can reduce the risk of vision loss for patients with occult wet age-related macular degeneration (AMD).
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
